Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y.--(BUSINESS WIRE)--June 27, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced today that its ex- U.S. partner for Tarceva® (erlotinib), Roche, received a positive opinion from...
MELVILLE, N.Y., Jun 02, 2005 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced the issuance of U.S. Patent No. 6,900,221 by the United States Patent and Trademark Office....
PRNewswire DEERFIELD, Ill. Astellas US LLC and Astellas Pharma US, Inc. ("Astellas") along with ITEM Development AB ("Item") announced today that they have filed a patent infringement lawsuit in...
Additional Milligram to Milligram Conversion Study Shows Equivalency of Prograf to MR Prograf SEATTLE, May 24, 2005 – Two studies presented today at the 6th American Transplant Congress (ATC)...
One Study of Early Steroid Withdrawal Reduced Cholesterol Levels and Decreased Onset of Post Transplant Diabetes SEATTLE, May 24, 2005 -- Early steroid withdrawal along with the use of tacrolimus...
Follow U.S. news
